The home health care company released its third quarter financial results ahead of its pending merger with UnitedHealth Group
Monday, November 11, 2024

BATON ROUGE, Louisiana—Amedisys Inc., a health care at home company aiming to deliver home health, hospice and acuity care services, reported its financial results for its third quarter of 2024, which include the three-month and nine-month periods that ended Sept. 30. Additionally, the company said due to its pending merger with UnitedHealth Group Inc., it will not conduct a quarterly earnings call to discuss the third quarter results.

The company’s third quarter financial results are detailed below.

Three-Month Period (Ended Sept. 30)

  • Net service revenue increased $31.5 million to $587.7 million, compared to $556.2 million in 2023.
  • Net income attributable to Amedisys Inc. of $16.9 million—which is inclusive of merger-related expenses totaling $16.7 million—compared to net income attributable to Amedisys Inc. of $26.0 million in 2023—which is inclusive of merger-related expenses totaling $5.0 million.
  • Net income attributable to Amedisys Inc. per diluted share of $0.51, compared to $0.79 in 2023.

Adjusted Quarterly Results

  • Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $58.1 million compared to $57.9 million in 2023.
  • Adjusted net income attributable to Amedisys Inc. of $33.2 million, compared to $32.2 million in 2023.
  • Adjusted net income attributable to Amedisys Inc. per diluted share of $1.00, compared to $0.98 in 2023.

Nine-Month Period (Ended Sept. 30)

  • Net service revenue increased $84.7 million to $1,750.3 million compared to $1,665.6 million in 2023.
  • Net income attributable to Amedisys Inc. of $63.6 million—which is inclusive of merger-related expenses totaling $49.2 million—compared to net loss attributable to Amedisys Inc. of $29.1 million in 2023—which is inclusive of merger-related expenses totaling $131.2 million.
  • Net income attributable to Amedisys Inc. per diluted share of $1.93, compared to net loss attributable to Amedisys Inc. per diluted share of $0.89 in 2023.

Adjusted Year-to-Date Results

  • Adjusted EBITDA of $191.1 million, compared to $190.4 million in 2023.
  • Adjusted net income attributable to Amedisys Inc. of $110.7 million, compared to $109.8 million in 2023.
  • Adjusted net income attributable to Amedisys Inc. per diluted share of $3.35, compared to $3.36 in 2023.

The company’s full 2024 third quarter earnings release can be found here.